Although a promising strategy, the mesenchymal stem cell (MSC)-based therapy of cartilage defects is sometimes accompanied with chronic inflammation during the remodeling status, which may hinder cartilage regeneration. During this process, the inflammatory cytokine tumor necrosis factor α (TNFα) plays an important role and may be a potential target. In this study, we investigated the effect of Tnfα RNA interference by introducing a functional and highly safe carbon dot (CD)-SMCC nanovector synthesized by bioconjugation of CDs with a protein crosslinker, sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC), as the vehicle of the silenced TNFα (siTnfα) on chondrogenesis of MSCs. The results showed that CD-SMCC displayed intense fluorescence with well-dispersed and positively charged properties, which favored effective binding and delivering of siTnfα into the MSCs. CD-SMCC-siTnfα nanoformula also exhibited considerably high transfection efficiency and nearly no cytotoxicity, which is preferred over commercial polyethyleneimine. Interference of Tnfα by CD-SMCC-siTnfα markedly promoted the chondrogenesis of MSCs, as indicated by upregulating cartilage-specific markers. Furthermore, in vivo exploration indicated that CD-SMCC-siTnfα transfected MSCs accelerated cartilage regeneration. In conclusion, this study demonstrated that in combination with the novel CD-SMCC nanovector, targeting Tnfα may facilitate stem cell-based therapy of cartilage defects. 2019;8:724-736 
INTRODUCTION
Mesenchymal stem cells (MSCs) have recently attracted much attention as sources for the clinical therapy of a variety of diseases [1, 2] , including cartilage injury, due to their ease of expansion and wide range of functions [3, 4] . Recruited MSCs can be specifically induced along the chondrogenic lineage in the presence of specific growth factors, molecules, and epigenetic modifications. However, the immune modulation capability of MSCs is somehow suppressed by chronic inflammation [5] during regeneration [6] , which impairs the chondrogenesis of MSCs and restrains the major constituent of the cartilage matrix (type II collagen), thus remaining a challenge for MSC therapy of cartilage defects.
Notably, tumor necrosis factor-α (TNFα) is one of the proinflammatory cytokines mediating local inflammatory processes in the joint and has an inhibitory effect on chondrogenesis. Elevated TNFα is detected in synovial tissue and fluid during the cartilage destruction cascade [7] , which suppresses the synthesis of cartilage matrix (e.g., aggrecan and type II collagen) [8, 9] . The potential mechanism may involve TNFα that activates a transcription factor, NF-κB, which in turn inhibits the synthesis of SOX9, which is a crucial transcription factor required for chondrogenic differentiation [10, 11] . TNFα also induces cell apoptosis in chondrocytes [12] and inhibits the migration of chondrogenic progenitor cells from nonfibrillated osteoarthritic cartilage [13] . Interference of TNFα obviously eases cartilage degeneration and promotes cartilage regeneration in post-traumatic arthritis [14, 15] . These findings suggest that TNFα may influence chondrogenic differentiation and may be one of the potential targets for MSC therapy. mRNA silencing of TNFα in MSCs by using small interfering RNA (siRNA)-mediated RNA interference (RNAi) may enhance chondrogenesis.
Successful gene delivery requires that the vehicles have favorable biocompatibility to avoid the elicitation of an adverse host immune response, as well as high transfection efficiency. Among the various vehicles, nanoparticles have attracted the most attention due to their unique properties, including as biosafety, flexibility, ease of formulation, and high delivery efficiency [16] . Among the various carriers, quantum dots (QDs) and carbon dot (CD)-based gene delivery systems are two of the most widely used fluorescent delivery systems [17, 18] . In a previous study, we reported on QD nanovectors modified by sulfosuccinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (sulfo-SMCC) for gene delivery and gene targeting in MSCs [19] . Although efficient in gene silencing, the heavy metal toxicity of QDs hinders its application to gene therapy in vivo [20] . Another fluorescent nanomaterial with both favorable biocompatibility and monodispersity, CDs have been proven to be excellent and efficient gene delivery vectors [21] and may replace QDs as the leading carrier in gene transfer. However, the gene may not bind closely to CDs without optimized surface modification [22] . A previous study from our laboratory demonstrated that QDs bioconjugated with sulfo-SMCC can form a stable thioether bond [19] , which retained the integrity of siRNA [23] and greatly increased the transfection efficiency [24] . Sulfo-SMCC contains N-hydroxysuccinimide ester and maleimide groups, allowing stable covalent conjugation of amine-containing and sulfhydryl-containing molecules [25] . This may shed light on the modification of CDs.
Based on our previous study, we synthesized CD-SMCC by bioconjugation of CDs with SMCC for the gene transfer of silenced TNFα (siTnfα) in MSCs to assess the effects of siTnfα on chondrogenic differentiation, with the intention of enhancing chondrogenesis of MSCs and further cartilage regeneration in vivo (Fig. 1) . Polyethyleneimine (PEI) was used as the control. This study may provide new insight into cartilage repair.
MATERIALS AND METHODS

Reagents and Chemicals
α-Minimum essential medium (α-MEM, Gibco, Shanghai, China), trypsin, and fetal bovine serum (FBS) were obtained from Gibco BRL (Invitrogen Co., Carlsbad, CA). PEI (25 kDa) was purchased from Sigma (Shanghai, China). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Sigma (St. Louis, MO). Amine functionalized water-soluble CDs were purchased from Janus (Nanjing, China), whereas thiolmodified FAM-labeled siRNAs (Tnfα-siRNA sequence: GGU UCU CUU CAA GGG ACA ATT) were purchased from Sangon Biotech (Shanghai, China). Fifty microliters of CDs (10 mg/ml) were diluted with borate buffer to form a 200 μg/ml solution and filtered through a 0.22-μm filter, followed by the addition of 10 μl of sulfo-SMCC (Life Technologies, Shanghai, China) solution. The mixture was incubated and shaken in a thermomixer (Eppendorf, Germany) at 300 rpm for 1 hour at 37 C. A desalting column equilibrated with MES buffer was prepared. After collecting the fluorescent fraction, the activated CD-SMCC was passed through the equilibrated desalting column and eluted with MES after centrifugation to remove aggregates. According to the protocol, the thiol-modified siTnfα was diluted with diethyl pyrocarbonate water to be prepared as a working solution (4 μg/ml). The CD-SMCC-siTnfα complexes at different weight ratios (CD-SMCC to siTnfα) were formulated by blending an equal volume of CD-SMCC solution with the siTnfα solution, which was vortexed for 1 minute. After half an hour, the CD-SMCC-siTnfα complexes were harvested and stored at 4 C for subsequent experiments.
Characterization Studies
The average particle size of the CDs and CD-SMCC-siTnfα complexes were measured by dynamic light scattering (DLS) analysis. CD-SMCC solution was dropped on a cover glass and then analyzed by a fluorescence microscope (BX53, Olympus, Tokyo, Japan) under ultraviolet (UV; 330-385 nm), blue (460-495 nm), and green (530-550 nm) light excitation, respectively. The fluorescence emission spectra of CD-SMCC were detected using a spectrofluorometer (RF-5301PC, Shimadzu, Japan). UV-visible absorbance spectra of both CDs and CD-SMCC were recorded using a microplate reader (Mutiskan Go, CA). Fourier transform infrared (FT-IR) spectra of both CDs and CD-SMCC were obtained using a SPECTRUM100 Spectrometer (Perkin Elmer, MA) in the frequency range of 500-4,000 cm −1 . The zeta potential (surface charge) of the CD-SMCC-siTnfα complex was determined by a Zeta Sizer Nano Z apparatus (Malvern, U.K.).
Gel Electrophoresis
To examine the binding effect of CD-SMCC in gene delivery, an agarose gel retardation study was conducted using CD-SMCCsiTnfα complexes with various weight ratios of 2:1, 5:1, 10:1, 20:1, and 40:1. The samples were loaded on a 1% agarose gel containing ethidium bromide (0.5 μg/ml) after mixing with loading buffer. After running the gel at 90 V for 20 minutes, the gel was imaged with a gel imager (BIO-RAD Laboratories, Hercules, CA).
Cell Culture
The MSCs were flushed from the femur and tibia of rats with a syringe containing 1 ml of phosphate-buffered saline (PBS) and then cultured in α-MEM medium (Gibco) supplemented with 10% FBS, 100 units per milliliter penicillin, and 100 μg/ml streptomycin at 37 C in a 5% CO 2 humidified incubator. The medium was replaced every 3 days, and MSCs of passage 3 were used.
Cytotoxicity of CD-SMCC-siTnfα
To evaluate the cytotoxicity of CD-SMCC-siTnfα complexes, the MTT assay was used. MSCs were seeded in 96-well plates at 5,000 cells per well, and CD-SMCC-siTnfα complexes (20 μl) with varied weight ratios were added in each well. PEI (25 kDa) was used as the control. After 72 hours of incubation, the MTT stock solution was added, followed by a 4-hour incubation at 37 C. Then, the medium was removed, and 200 μl of dimethyl sulfoxide (Gibco) was used to dissolve the formazan product. The absorbance of each well was measured at 570 nm by a microplate reader (Thermo Fisher Scientific, U.K.). All experiments were performed with six replicates.
In Vitro Transfection 1 × 10 5 MSCs were seeded into each well of 6-well plates. After 24 hours, the complete culture medium was changed to α-MEM without serum and antibiotics. The CD-SMCC-siTnfα complexes with an optimal weight ratio were added in each well. The PEI-siTnfα complexes were used as the control. After incubation for 12 hours, the supernatant was discarded, and the MSCs were rinsed with PBS twice. Then, complete culture medium was added to the MSCs.
Transmission Electron Microscopy Analysis
The morphology of the CDs and CD-SMCC-siTnfα complexes were observed by transmission electron microscopy (TEM; H-7650, Hitachi, Japan) at an accelerating voltage of 200 kV. All samples were dried and analyzed by TEM.
Transfected MSCs by CD-SMCC-siTnfα were also examined by TEM. Briefly, the transfected cells were fixed with 2.5% glutaraldehyde for 4 hours at 4 C and then treated with 1% osmium tetroxide at room temperature. The samples were cut into 60 nm ultrathin sections and mounted onto a copper mesh. The sections were analyzed by TEM (H-7650, Hitachi, Japan).
Confocal Laser Scanning Microscope Analysis
To track the cellular uptake of the CD-SMCC-siTnfα complexes, an assay by confocal laser scanning microscope (CLSM) was used. The MSCs were seeded in a confocal dish at a density of 1 × 10 5 cells per well. After 24 hours of culture, the medium was replaced by 2.25 ml of FBS-free α-MEM medium, along with 250 μl of the CD-SMCC-siTnfα complexes of optimal dose. After being cultured at 37 C for 2 hours, 4 hours, and 8 hours, the cells were rinsed with PBS three times. Then, all the samples were stained with RedDod1 for 15 minutes and LysoTracker Yellow for 30 minutes in the dark. Confocal images were obtained at each time point using a CLSM (Nikon A1, Japan). 
Flow Cytometry
In Vitro Chondrogenic Induction
Briefly, in vitro chondrogenic induction was performed as previously reported [26] . Chondrogenic inducing medium was based on α-MEM (Gibco) containing 10% FBS, 1% insulintransferrin-selenium solution (Gibco), 100 nM dexamethasone (Sigma-Aldrich, Billerica, MA), 50 μg/ml ascorbic acid (Sigma), and 10 ng/ml TGF-β1 (Prope Tech, Rocky Hill, NJ). After 7, 14, and 21 days of induction, chondrogenic effects were evaluated by studying GAG content and chondrocytic specific mRNAs identified by PCR.
Measurement of Total DNA and GAG Content
Four groups were investigated, including untreated MSCs (untreated), CD-SMCC transfected MSCs (CD-SMCC), PEI-siTnfα (PEI-Si), and CD-SMCC-siTnfα transfected MSCs (CD-SMCC-Si), which were cultured for 7, 14, and 21 days. The samples were fully immersed in 60 μg/ml proteinase K (Sigma) solution for 10 hours at 60 C for digestion, followed by the addition of Hoechst 33258 (Sigma) for 5 minutes. The fluorescence was examined with a microplate fluorescence reader (FLX800, BioTec, Burlington, VT) at 460 nm by using calf thymus DNA as a standard. The total glycosaminoglycan (GAG) production was measured by the 1,9-dimethylmethylene blue (DMMB) colorimetric method [27] . The proteinase K-digested specimens were mixed with DMMB solution and the absorbance value was read in a microplate reader (Thermo, Karlsruhe, Germany) at 525 nm. The amount of GAG production was normalized to the total DNA content to evaluate the biosynthetic activity of the cells in all groups.
Real-Time PCR Analysis
To detect the expression of Tnfα and cartilage-specific genes in transfected MSCs, including aggrecan (Acan), Col2a1, and SRY-related high mobility group-box gene 9 (Sox9), real-time (RT)-PCR analysis was performed. Total RNA was extracted using an RNA isolation kit (Invitrogen Life Technologies), as instructed by the manufacturer. After the reverse transcribed reaction, real-time fluorescent quantitative PCR was detected by the LightCycler R 96 (Roche, Switzerland). The conditions of RT-PCR were as follows: 40 cycles of 95 C for 10 minutes, 94 C for 15 seconds, and 60 C for 1 minute. All primers (Supporting Information Table S1 ) were designed based on established GenBank sequences, with β-actin (Actb) as an internal control for the assessment of PCR efficiency. Ct values were also determined.
Animal Model
The animal study was approved by the Committee on the Ethics of Animal Experiments of Guangxi Medical University (2017-02-03). The animal experiment conditions were as previously stated (animal experimental statement) [3] . Ten-week-old male SD rats were anesthetized using 2.5% sodium pentobarbital (30 mg/kg). After routine skin preparation, a medial para-patellar skin incision was made, and the knee joint and chondral surface of the femur was fully exposed by lateral dislocation of the patella. By using a punch, a full thickness cylindrical cartilage defect (2.5 mm in diameter, 1.0 mm in depth) was created in the center of the patellar groove. Approximately 0.4 ml of the cell clusters (1 × 10 5 cells per milliliter) were injected into the defect site. Then, the patella was carefully relocated, and the incisions were tightly sutured layer by layer. The SD rats were divided into four groups: nontreated MSCs (untreated), CD-SMCC transfected MSCs (CD-SMCC), PEI-siTnfα transfected MSCs (PEI-Si), and CD-SMCC-siTnfα transduced MSCs (CD-SMCC-Si). Each group contained eight rats, and the experiments were performed on the bilateral knee joints of each rat.
Macroscopic Observation
After 4 and 8 weeks of therapy, the rats were sacrificed by an intravenous overdose of pentobarbital, and their knee joints were harvested. The knee joints from each group were examined and photographed for evaluation. Finally, the samples were fixed in 4% paraformaldehyde for hematoxylin-eosin (H&E) staining, Safranin-O staining, and immunohistochemistry. The International Cartilage Repair Society (ICRS) macroscopic score was performed [28] .
Histological and Immunohistochemical Evaluation
After fixing in paraformaldehyde, the samples were decalcified and embedded in paraffin and cut into 5-μm sections. Paraffin sections were deparaffinized in xylene and hydrated with graded alcohol. H&E and Safranin-O stains were used to evaluate morphology and GAG accumulation of engineered cartilage. The histological score was blindly observed by three independent investigators (S.C., L.Y., and J.T.) using an established histological scoring system [29] .
The secretion of type II collagen and TNFα in the regenerated tissue was analyzed with an immunohistochemical staining kit (Bioss, Beijing, China). Briefly, the sections were incubated with 3% H 2 O 2 for 10 minutes to exclude endogenous peroxidase activity. Then, the samples were blocked with goat serum for 10 minutes, followed by the incubation of mouse anti-rabbit collagen type II (COL2A1, Acris Antibodies GmbH, AF5710) and TNFα (Boster, Wuhan, China) antibodies with 1:200 dilutions overnight. After incubating with the secondary antibody, the samples were visualized by a 3,3 0 -diaminobenzidine tetrahydrochloride kit (Boster, Wuhan, China) before brief counterstaining with hematoxylin. Images were viewed under an upright microscope (Olympus BX53, Tokyo, Japan).
Statistical Analysis
Data analyses were performed using SPSS 16.0 and GraphPad 5.0. One-way analysis of variance and Tukey's test were used. The statistically significant value was set at p < .05.
RESULTS AND DISCUSSION
Characterization of CD-SMCC-siRNA
The morphology and structure of CDs and CD-SMCC-siTnfα were explored by TEM. As shown in Figure 2A , 2B, both CDs and CD-SMCC-siTnfα displayed monodisperse and spherical morphology, with a diameter range of 4-10 nm and 13-22 nm, respectively. Covalent bioconjugation to SMCC-siTnfα increased the size of the CDs, implying that there existed slight aggregation of nanoparticles during the process of conjugation. Based on the DLS analysis, the average size of CD particles was approximately 7.4 nm AE 1.3 nm ( Fig. 2A) and that of CD-SMCC-siTnfα complexes was 16.1 nm AE 2.8 nm (Fig. 2B) CD-SMCC has a potent affinity for macromolecular siRNA, which could protect the RNA from nuclease degradation and assist cellular uptake. Figure 2C shows that CD-SMCC in solution presented blue, green, and red luminescence, respectively, which demonstrated that the luminescence property of CDs did not change after modification. The excitation-dependent photoluminescence emission spectra were further used to evaluate the wavelengthdependent feature of CD-SMCC. The excitation wavelengths ranged from 220 nm to 400 nm, with a peak intensity at 360 nm (Fig. 2D) . It has been reported that the different origins of photoluminescence in CDs lead to the differently distributed emission energy traps on the surface [30] . As shown in Figure 2E , the ultraviolet absorption spectrum of CDs was observed at 345 nm. After modification with SMCC, the peak was observed at 330 nm with a minor blueshift, which is due to the n-π* transition of the C O group. FT-IR spectra were further recorded to identify the organic functional groups on SMCC-modified CDs. As shown in Figure 3F , compared with the spectrum of CDs, peaks of CD-SMCC at 2,939 cm . Both CDs and CD-SMCC-siTnfα complexes exhibited positive charges by zeta potential measurements, which averaged 17.06 mV AE 2.3 mV and 21.33 mV AE 1.4 mV, respectively (Fig. 2G) . In contrast, the siRNA surface showed negative charges of −17.13 mV AE 1.8 mV. The charge reduction (10.05 mV AE 2.1 mV) of CD-SMCC-siTnfα indicated successful covalent bioconjugation.
Binding Efficiency of CD-SMCC-siRNA Complexes
It has been generally accepted that naked CDs can hardly be conjugated with dsRNA, which necessitates surface functionalization of CDs [31] . We proposed that the activated CD-SMCC has great potential in binding with siRNA and tested the affinity of CD-SMCC for siRNA with various weight ratios of 2:1, 5:1, 10:1, 20:1, and 40:1 by agarose gel electrophoresis. As shown in Figure 2H , the intensity of the siTnfα migration bands gradually decreased with the increase in weight ratios. When the ratio was equal to or above 20:1, almost no RNA would migrate toward the anode, demonstrating that the RNA was fully bound to CD-SMCC. These results indicated that CDs activated by SMCC were endowed with excellent complexing ability with siRNA, which is essential for gene delivery.
Cytotoxicity of CD-SMCC-siRNA Complexes
To study the chondrogenic potential of MSCs by immune modulation, the carrier is required to have not only high transfection efficiency but also exceedingly low cytotoxicity to elicit minimal host response. The MTT assay was used to evaluate the cytotoxicity of the CD-SMCC-siTnfα complexes to rat MSCs, with PEI-siTnfα as the control. As shown in Figure 2I , the cytotoxicity of CD-SMCC-siTnfα complexes with different weight ratios from 2:1 to 20:1 was minimal, with more than 90% cell viability. However, cell viability was slightly less when the ratio increased to 40:1. This result implied that the CD-SMCC-siTnfα complexes had dose-dependent toxicities. In contrast, PEIsiTnfα with the same weight ratios exhibited noticeable dosedependent cytotoxicity. Specifically, the cell viability dropped below 70% when the ratio was >6:1. Activated CD-SMCC is advantageous when compared with the conventional commercial transfection reagent PEI, has favorable biocompatibility and may not cause an adverse immune response.
Cellular Uptake of the CD-SMCC-siRNA Complexes by MSCs
To investigate the cellular ultrastructural response to CD-SMCCsiTnfα, transfected MSCs at different time points were detected by TEM. As shown in Figure 3A , 3B, multiple internalized CD-SMCC-siTnfα clustered onto the surface of the cytomembranes at 2 hours post-transfection, followed by the extension of numerous cellular filopodia toward nanoparticle clusters to wrap them. After 4 hours, most of the endocytosed CD-SMCCsiTnfα escaped from the cell membrane and aggregated from the early endosomes to the late ones (Fig. 3B, 3C ). Eight hours later, they gradually moved closer to the nucleus, where the delivered genes were released (Fig. 3D, 3E) . Sometimes, several endosomes were broken, which allowed the discharged CD-SMCC-siTnfα to enter the cytoplasm (Fig. 3D, 3F ). This study confirms the assertion that enveloped nonviral complexes experience endosome escape based on the proton sponge hypothesis [32, 33] . Finally, most of the CD-SMCCsiTnfα complexes that entered the cells were observed in the cytosol of MSCs after a 12 hours transfection (Fig. 3G) . Overall, these findings demonstrated that the CD-SMCC bundled siTnfα successfully penetrated the endocytosis pathway to reach the cytoplasm and escaped endosome wrapping.
The Transfection Process of CD-SMCC-siRNAs in MSCs
Negatively charged siRNA is easily degraded by nucleases, making it difficult to enter the cells through the cell membrane [30, 34, 35] . A functional nanocomposite formulation can protect siRNAs from degradation [36] . To confirm the protection of active CD-SMCC nanoparticles from siRNA enzymolysis, we studied the cellular internalization of CDs by CLSM. It was observed that large numbers of nanoparticles indicated by blue fluorescence and FAM-siTnfα (green) were internalized into the cells with RedDod1-labeled nuclei (Fig. 4) . At 2 hours post-transfection, CD-SMCC and FAM-siTnfα assembled around the cell membranes. After 4 hours, most uptaken nanoparticles were present in the endosomal compartments, whereas the green FAM-siTnfα and the blue CDs were predominantly located in the yellow-labeled organelles, which suggested that the CD-SMCC-siTnfα complexes were retained in the endosomes or lysosomes. Eight hours later, an increasing number of CDs were distributed at the periphery of the nucleus instead of the organelles, which indicated endosomal escape. During the whole process, green fluorescence by FAM-siTnfα intensified in a timedependent manner. These findings mirror the observations from the cellular uptake mechanism of CD-SMCC-siTnfα by TEM, demonstrating effective transfection. In addition, a remarkable increase in green fluorescence appeared in the cytoplasm, which revealed effective silence and stable expression of siRNA released from CD-SMCC-siTnfα complexes. This remarkable fluorescent feature endows CD-SMCC with an intrinsic ability for both gene delivery and bioimaging.
Transfection Efficiency of CD-SMCC-siRNA Complexes
Flow cytometry was used to quantitatively measure the transfection efficiency of MSCs. The results showed that only 0.10% of the untreated MSCs were positive, whereas 39.95%, 83.64%, and 64.38% of the MSCs were positive followed by incubation with the CD-SMCC-siTnfα complexes for 6 hours, 12 hours, and 24 hours, respectively (Fig. 5A) . Among the various time points, 12 hours was the best for transfection. For the weight ratios of CD-SMCC-siTnfα complexes, 20:1 (86.69%) was much higher than 10:1 (53.78%) and 40:1 (63.41%), consistent with the findings by electrophoresis. A higher dose (40:1) inversely led to the decline of transfection efficiency because of the increased cytotoxicity, which was also verified by MTT analysis. Under optimal weight ratios and transfection time (20:1, 12 hours) 87.93% of the MSCs administered CD-SMCC-siTnfα were positive, which was markedly higher than those administered PEI-siTnfα (69.89%). The transfection efficiency of the CD-SMCC-siRNA was higher than commercial PEI, which may be due to the small particle size of CDs and the aggregation effects when combined with the siRNA to prevent enzymolysis [37] . The result demonstrated that CD-SMCC was a safe vector with high efficiency. 
Gene Silencing Efficiency of CD-SMCC-siTnfα
A real-time PCR assay was performed to evaluate the gene silencing efficiency of CD-SMCC-siTnfα complexes at the mRNA level. As shown in Figure 5B , mRNA expression levels of Tnfα exhibited a time-dependent increase in each group. No significant differences were found between the untreated MSCs and CD-SMCC groups. Compared with the untreated MSCs, the expression of Tnfα was markedly downregulated in both the PEI-siTnfα (PEI-Si) and CD-SMCC-siTnfα transfected MSC (CD-SMCC-Si) groups at each time point (p < .05). Significantly lower gene expression was shown in CD-SMCC-Si than that in the PEI-Si group (p < .05), with the gap deepening in a timedependent manner. The results indicate that CD-SMCC may better prevent siRNA from enzymatic degradation and guarantee the effective delivery of siRNA to the cytoplasm compared with commercial PEI, which is beneficial to improving the efficiency of gene silencing. In particular, the effect of gene silencing becomes more pronounced after a long period of transfection.
Suppression of Tnfα by CD-SMCC-siTnfα Promoted GAG Production in MSCs
To further investigate the effect of Tnfα silencing by transfection of CD-SMCC-siTnfα with an optimized dose on chondrogenic differentiation of MSCs, we measured GAG secretion given as a ratio of GAG to DNA content by biochemical assays after 7, 14, and 21 days. As shown in Figure 5C , the DNA content exhibited a time-dependent increase in each group, which suggested that the numbers of cells increased with time. During the process, there was no significant difference among the DNA content in the untreated, CD-SMCC and CD-SMCC-Si groups (p > .05), indicating that CD-SMCC has negligible toxicity. In contrast, the DNA content of the PEI-Si group was significantly decreased after 14 days (p < .05), showing slight cytotoxicity of PEI. GAG content showed an increase in a time-dependent manner in the CD-SMCC-Si and PEI-Si groups, which changed little with time in the untreated and CD-SMCC groups (Fig. 5D) . Compared with the untreated group, the GAG content rapidly increased in the CD-SMCC-Si group after 7 days, whereas it increased in the PEI-Si group after 14 days. At each time point, the GAG content was significantly higher in the CD-SMCC-Si group than that in the PEI-Si group (p < .05). Particularly, the GAG secretion of the CD-SMCC-Si group was 1.87-, 2.8-, and 5.05-fold higher than that in the untreated group at 7, 14 and 21 days, respectively (p < .05). These findings demonstrated that the interference of Tnfα in MSCs by CD-SMCC-siTnfα transfection promotes chondrogenic differentiation by increasing the production of GAG, which is a marker of cartilage matrix.
Tnfα Silencing by CD-SMCC-siTnfα Upregulated the Expression of Cartilage-Specific Genes in MSCs
To detect the effect of Tnfα silencing by CD-SMCC-siTnfα transfection on the chondrogenic potential of MSCs at the mRNA level, we used RT-PCR to evaluate the expression of chondrogenic-specific genes including Sox9, Col2a1, and Acan. As shown in Figure 5E -5G, there was a slight time-dependent increase in the mRNA expression levels of these genes in the untreated MSC (untreated) and CD-SMCC transfected MSC (CD-SMCC) groups, whereas there was a sharp increase with time in the PEI-siTnfα (PEI-Si) and CD-SMCC-siTnfα transfected MSC (CD-SMCC-Si) groups. Among all the groups, the CD-SMCC-Si group showed the highest expression level at each time point (p < .05, Fig. 5E-5G ). Except at day 7, the expression of chondrogenic-specific genes in the CD-SMCC-Si group was significantly higher than that in the PEI-Si group. The results indicate that the high transfection efficiency and biosafety of CD-SMCC-siTnfα contribute to the potent silencing effect, which further promotes the chondrogenic potential of MSCs by immune modulation. It has been reported that the pro-inflammatory responses of MSCs were inhibited by using the intracellular release of a small-molecule inhibitor of NF-kB by microparticles [38] . As NF-kB can be upregulated by TNFα in MSCs [39, 40] , inhibition of Tnfα may be a potential target for gene therapy of cartilage defects [10, 41] .
Enhanced Therapeutic Effect of CD-SMCC-siTnfα Transfected MSCs on Cartilage Regeneration
Numerous studies have demonstrated that TNFα induces chondrocyte apoptosis and prevents cartilage matrix synthesis (e.g., aggrecan and type II collagen) [12, 42] . Conversely, inhibition of TNFα can repair the degeneration of the cartilage matrix [43] . Therefore, we hypothesized that knockdown of Tnfα may contribute to the acceleration of cartilage regeneration. To validate our hypothesis, MSCs transfected with CD-SMCC-siTnfα and PEI-siTnfa were implanted into a cartilage defect model, along with a control. The conditions of all rats were almost the same before and after the surgery. All rats were included in the analysis below. Upon (Fig. 6A) . Four weeks post-transplantation, defects in the untreated and CD-SMCC (empty vector treated) groups were blank with little tissue. In contrast, glossy white regenerated tissues integrated with the surrounding tissues were observed in the defects of the CD-SMCC-Si and PEI-Si groups. Particularly, part of the neo-tissue in the CD-SMCC-Si group was almost indistinguishable from the surrounding tissue. Eight weeks after the operation, the defects in the control and CD-SMCC group were filled with a thin and irregular layer of fibrous tissue discernible from the surrounding tissues. In the CD-SMCC-Si and PEI-Si groups, the defects were mostly filled with opaque white cartilage-like tissue well integrated with the surrounding tissues. For the CD-SMCC-Si group, the margin between the neo-tissue and the original cartilage could hardly be discerned. The score of ICRS further confirmed the macroscopic evaluation. At each time point, the CD-SMCC-Si group scored the highest and was followed by the PEI-Si group, both of which were much higher than the untreated and CD-SMCC groups (Fig. 6B ).
To further confirm the effect of cartilage repair, histological evaluation of specimens was carried out. At 4 or 8 weeks after operation, H&E staining analysis (Supporting Information Fig. S1 ) and Safranin-O staining showed that the defects on the joint surface in untreated (Fig. 6Ca, 6Ce, 6Ci, 6Cm ) and CD-SMCC groups (Fig. 6C, 6Cb , 6Cf, 6Cj, 6Cn) were unfavorably repaired and were filled with mainly inflammatory cells, with a small amount of fibrous tissue. In addition, the boundary between the neo-tissue and the original cartilage tissue was clearly distinguishable in the two groups. Identified by Safranin-O, negative staining was shown in the defect of untreated (Fig. 6Ca, 6Ce, 6Ci, 6Cm ) and CD-SMCC groups (Fig. 6Cb, 6Cf, 6Cj, 6Cn) . Conversely, the newly regenerated tissue progressed from fibrous cartilage-like to hyaline cartilage-like tissue in both PEI-Si (Fig. 6Cc, 6Cg, 6Ck, 6Co ) and CD-SMCC-Si groups (Fig. 6Cd, 6Ch, 6Cl, 6Cp ). In addition, modicum inflammatory cells were dispersed in the defect at 4 weeks. Round chondrocytic cells embedded in the lacuna, a typical feature of hyaline cartilage, were observed in the defect after 8 weeks of therapy (Fig. 6Ck, 6Cl, 6Co, 6Cp) . Safranin-O staining also showed positive staining that intensified with time, indicating a time-dependent accumulation of proteoglycans, which are markers of the cartilage matrix. In the CD-SMCC-Si group, the most abundant matrix was shown in the defect, with an interface that was hardly distinguishable (Fig. 6Cl, 6Cp ) from the surrounding tissue. Histological scores further validated the observation at different times, in the order of CD-SMCC-Si, PEI-Si and untreated/CD-SMCC (Fig. 6D) . The CD-SMCC group scored almost the same as the untreated group, not only in the macroscopic evaluation but also in the histological assay, which demonstrated the safety of CD-SMCC.
Immunohistochemical staining for type II collagen specific to the cartilage matrix showed intense positive staining (brown) in the regenerated tissue of the PEI-Si and CD-SMCC-Si groups and negative staining in those of the untreated and CD-SMCC groups. Stronger staining of COL2A1 was observed in the CD-SMCC-Si group compared with the others, indicating the most deposited cartilage matrix (Fig. 7D) .
Reduced Inflammation by Therapy of CD-SMCC-siTnfα Transfected MSCs
For MSC-based therapy, the therapeutic efficacy of MSCs is often impaired by inflammation [44, 45] , in which TNFα plays a crucial role. Our immunohistochemical findings showed intense positive staining of TNFα during the process of therapy by MSCs (untreated group), indicating the occurrence of inflammation (Supporting Information Fig. S2A, S2C, S2E, S2G) . However, after introduction of CD-SMCC-siTnfα transfection, Fig. S2B, S2D , S2F, S2H), as evidenced by almost negative staining. The results were negatively correlated with the expression of type II collagen, demonstrating that TNFα may be an inhibitor in chondrogenic differentiation. Thus, suppression of TNFα promotes chondrogenic differentiation by inhibition of host inflammation, favorable for cartilage regeneration.
CONCLUSION
In summary, this is the first study to report novel multifunctional and highly biocompatible CD-SMCC nanoparticles as a gene carrier to transfer siTnfα into MSCs in an attempt to promote chondrogenic differentiation. CD-SMCC had favorable biocompatibility, low toxicity, high transfection efficiency and excellent complexing ability with siRNA, which is preferred over the commercial transfection reagent, PEI25k. In addition, it was observed that the silencing of TNFα (siTnfα) in MSCs markedly promoted the chondrogenic differentiation of MSCs and further accelerated cartilage regeneration in vivo. This work may suggest potential for the application of gene therapy in cartilage tissue engineering. 
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